Literature DB >> 22258389

Frequent development of chronic obstructive pulmonary disease in primary SS--results of a longitudinal follow-up.

Thomas Mandl1, Sandra Diaz, Olle Ekberg, Roger Hesselstrand, Eeva Piitulainen, Per Wollmer, Elke Theander.   

Abstract

OBJECTIVES: To study the longitudinal development of pulmonary function in patients with primary SS (pSS) and its association with respiratory symptoms, pulmonary radiographic findings and clinical features of pSS.
METHODS: Forty-one pSS patients, previously evaluated by pulmonary function tests (PFTs), were included in the study. The patients were studied at baseline and follow-up by PFT and at follow-up also by high-resolution CT scan of the lungs, the St George's Respiratory Questionnaire and by inflammatory and serological tests. The PFT results were compared with previously studied population-based controls, standardizing results with regard to gender, age, height, weight and tobacco consumption.
RESULTS: The mean follow-up time was 11 years. The pSS patients displayed signs of both obstructive and restrictive lung disease at baseline and at follow-up, and deteriorated in forced expiratory volume in 1 s (FEV(1)), ratio of FEV(1) to vital capacity and in diffusing capacity for carbon monoxide during follow-up. Chronic obstructive pulmonary disease (COPD) was diagnosed in 37% of the pSS patients at follow-up. In pSS patients, respiratory symptoms and radiographic abnormalities were common, although with a poor association with PFT variables.
CONCLUSION: The pSS patients showed signs of both obstructive and restrictive pulmonary disease and COPD commonly developed during follow-up. Respiratory symptoms and radiographic abnormalities were common but poorly associated with PFT in pSS patients.

Entities:  

Mesh:

Year:  2012        PMID: 22258389     DOI: 10.1093/rheumatology/ker409

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

Review 1.  Pulmonary manifestations of Sjögren's syndrome.

Authors:  George Stojan; Alan N Baer; Sonye K Danoff
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

2.  Risk of Chronic Obstructive Pulmonary Disease in Female Adults With Primary Sjögren Syndrome: A Nationwide Population-Based Cohort Study.

Authors:  Te-Chun Shen; Biing-Ru Wu; Hsuan-Ju Chen; Cheng-Li Lin; Chang-Ching Wei; Chia-Hung Chen; Chih-Yen Tu; Te-Chun Hsia; Chuen-Ming Shih; Wu-Huei Hsu; Fung-Chang Sung; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

3.  Respiratory symptoms are poor predictors of concomitant chronic obstructive pulmonary disease in patients with primary Sjögren's syndrome.

Authors:  Victor Strevens Bolmgren; Peter Olsson; Per Wollmer; Roger Hesselstrand; Thomas Mandl
Journal:  Rheumatol Int       Date:  2017-02-27       Impact factor: 2.631

Review 4.  Chronic obstructive pulmonary disease and rheumatic diseases: A systematic review on a neglected comorbidity.

Authors:  Irini Gergianaki; Ioanna Tsiligianni
Journal:  J Comorb       Date:  2019-01-07

Review 5.  Pulmonary Manifestations of Primary Sjögren's Syndrome: Underlying Immunological Mechanisms, Clinical Presentation, and Management.

Authors:  Sarthak Gupta; Marcela A Ferrada; Sarfaraz A Hasni
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

6.  Low Influenza, Pneumococcal and Diphtheria-Tetanus-Poliomyelitis Vaccine Coverage in Patients with Primary Sjögren's Syndrome: A Cross-Sectional Study.

Authors:  Jacques Morel; Hind Letaief; Philippe Guilpain; Xavier Mariette; Bernard Combe; Cédric Lukas
Journal:  Vaccines (Basel)       Date:  2019-12-21

7.  Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis.

Authors:  Shunsuke Uno; Takanori Asakura; Kozo Morimoto; Kimio Yoshimura; Yoshifumi Uwamino; Tomoyasu Nishimura; Yoshihiko Hoshino; Naoki Hasegawa
Journal:  BMC Pulm Med       Date:  2020-10-09       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.